Indonesia examines use of Sinovac, Pfizer Covid-19 vaccines for kids

Indonesia is currently examining the use of the Sinovac and Pfizer Covid-19 vaccines for people under 18 years of age after detecting many cases among children and youths

Indonesia
IANS Jakarta
2 min read Last Updated : Jun 26 2021 | 11:42 AM IST

Indonesia is currently examining the use of the Sinovac and Pfizer Covid-19 vaccines for people under 18 years of age after detecting many cases of the highly contagious Delta variant of the coronavirus among children and youths.

"We are currently reviewing which vaccines already have an EUA (Emergency Use Authorization) for young people. What we have observed is that there are two on our list; Sinovac for those aged three to 17 years old and Pfizer for those aged 12-17 years old," Health Minister Budi Gunadi Sadikin said at a virtual press conference on Friday.

China has approved the emergency use of its Sinovac vaccine for children as young as three-year-old, while the US has green-lighted the Pfizer jab for those as young as 12, reports Xinhua news agency.

Sadikin said the Health ministry has been conducting a study on vaccinating children, which will be released soon, and at the same time it has also continued to observe the developments and data related to effectiveness and side effects of vaccines administered to children in a number of countries.

"We can issue a comprehensive decision based on the data we have, policy data in other countries and health scientific data on the EUA that have been given to vaccine companies," said Sadikin.

Under its plan, the Southeast Asian country is currently working to inoculate the targeted 181.5 million people aged over 18, about 70 per cent of its total population, by March 2022.

According to the World Health Organization, Indonesia has so far administered 36,581,555 of the Covid-19 vaccines doses.

--IANS

ksk/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineIndonesia

First Published: Jun 26 2021 | 11:42 AM IST

Next Story